We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biomarkers Evaluate Kidney Injury in Cancer Patients

By LabMedica International staff writers
Posted on 17 Feb 2021
Immune checkpoint inhibitors (ICI) are monoclonal antibodies that can unleash the immune system by blocking surface molecules that serve as important breaks (or checkpoints) that mediate negative regulation of T cells. More...
ICI have substantially improved the prognosis for patients with a wide range of malignancies.

ICI therapy may induce a variety of immune related adverse events (iRAEs), including nephrotoxicity. The incidence of iRAE in patients receiving ICI can be as high as 85% depending on the target and the use of mono- or combination therapy. The most commonly affected organs are skin, endocrine glands, gastrointestinal tract, lungs and liver.

Nephrologists at the Mayo Clinic (Rochester, MN, USA) carried out a single center, retrospective observational study. They performed a search of the electronic medical records for all patients who had received an ICI and suffered an acute kidney injury (AKI) event between January 2014 and June 2020. There were 37 patients with ICI-AKI and 13 non-ICI AKI referents in the cohort for analysis. Clinical and laboratory features, including serum creatinine (SCr), serum C-reactive protein (CRP) and urine retinol binding protein/ urine creatinine(uRBP/Cr) levels at AKI event were evaluated.

The scientists reported that At time of AKI, SCr, CRP and uRBP/Cr were significantly higher in the ICI-AKI compared to the non-ICI-AKI patients (median [IQR] serum creatinine 2.0 [1.7, 2.9] versus1.5 [1.3, 1.6] mg/dL, serum CRP 54.0 [33.7, 90.0] versus 3.5 [3.0, 7.9] mg/L and urine uRBP/Cr 1,927 [1,174, 46,522] versus 233 [127, 989] mcg/g Cr, respectively). Compared to the referent group, time from ICI initiation to AKI was shorter in the ICI-AKI patients. Among the ICI-AKI group, complete renal recovery occurred in 39% of patients by three months; rechallenge occurred in 16 (43%) of patients, of whom three (19%) had recurrence of AKI. A pattern was observed with eGFR, which decreased in the ICI-AKI group as compared to the non-ICI-AKI at the time of AKI (median 28.9 [16.7, 37.8] versus 40.6 [38.9, 46] mL/min/1.73m2, respectively.

Sandra M. Herrmann, MD, a Nephrologist and the study's senior author, said, “Immune checkpoint inhibitors have improved the prognosis for patients with a wide range of malignancies including melanoma, non-small cell lung cancer and renal cancer. In some patients, this enhanced immune response may target kidney tissue, leading to acute kidney inflammation known as interstitial nephritis.”

The authors concluded that their study provided novel, important data for clinicians regarding the use of biomarkers in the routine evaluation of cause of AKI in patients on ICI therapy. These biomarkers could assist with discriminating ICI-AKI from other causes and may also help aid clinical decision-making related to both management and recurrence. They also described distinguishing clinical characteristics of patients with ICI-AKI, which may help with the diagnosis and possible prevention of ICI-AKI, by reinforcing the strategy of avoidance of acute interstitial nephritis (AIN) associated drugs in this type of patient. The study was published on February 1, 2021 in the journal Kidney International Reports.

Related Links:
Mayo Clinic


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
Gel Cards
DG Gel Cards
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.